Glycosyl-phosphatidylinositol-anchored interleukin-2 expressed on tumor-derived exosomes induces antitumor immune response in vitro

Tumori

Volumn 96, Issue 3, 2010, Pages 452-459

  Zhang, Jiamo ^a   Zhang, Yao ^a   Luo, Chunli ^a   Xia, Yuguo ^a   Chen, Honglin ^a   Wu, Xiaohou ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocytes; Exosomes; GPI; IL 2

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HEAT SHOCK PROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; MELANOMA ANTIGEN 1;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTRON MICROSCOPE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR DERIVED EXOSOME; WESTERN BLOTTING;

EID: 77954998657     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600313     Document Type: Article

References (35)

1. Wolfers J, Lozier A, Raposo G, Regnault A, Théry C,Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross priming. Nat Med, 7: 297-303, 2001. (Pubitemid 32224344)
2. McLellan AD: Exosome release by primary B cells. Crit Rev Immunol, 29: 203-217, 2009.
3. Thery C, Duban L, Segura E,Véron P, Lantz O, Amigorena S: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol, 3: 1156-1162, 2002. (Pubitemid 35469700)
4. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci, 19: 3365-3374, 2000.
5. Thery C, Zitvogel L, Amigorena S: Exosomes: composition, biogenesis and function. Nat Rev Immunol, 2: 569-579, 2002.
6. + CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol, 3: 205-211, 2006.
7. Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A: Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med, 7: 4, 2009.
8. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L: Malignant effusions and immunogenic tumour-derived exosomes. Lancet, 360: 265-305, 2002. (Pubitemid 34874721)
9. Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T: Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer, 90: 773-780, 2004. (Pubitemid 38406585)
10. Nguyen CL, Salem ML, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE: Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine, 21: 2318-2328, 2003.
11. Li YG, Wang ZP, Tian JQ, Tian BQ, Rodrigues R, Shang PF, Zhang T: Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cells in vitro. Cancer Invest, 27: 909-917, 2009.
12. Ikezawa H: Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol Pharm Bull, 25: 409-417, 2002.
13. Bumgarner GW, Shashidharamurthy R, Nagarajan S, D'Souza MJ, Selvaraj P: Surface engineering of microparticles by novel protein transfer for targeted antigen/drug delivery. J Control Release, 137: 90-97, 2009.
14. Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF: General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol, 81: 8666-8676, 2007 (Pubitemid 47242840)
15. Nagarajan S, Selvaraj P: Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Vaccine, 24: 2264-2274, 2006
16. Ji J, Li J, Holmes LM, Burgin KE, Yu X, Wagner TE, Wei Y: Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma tumor growth in mice. Mol Cancer Ther, 1: 1019-1024, 2002.
17. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res, 65: 5238-5247, 2005.
18. Nociari MM, Shalev A, Benias P, Russo C: A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Meth, 213: 157-167, 1998.
19. Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med, 3: 10, 2005.
20. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med, 3: 9, 2005.
21. André F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E, Zitvogel L: Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine, 20: A28-31, 2002.
22. Cho JA, Yeo DJ, Son HY, Kim HW, Jung DS, Ko JK, Koh JS, Kim YN, Kim CW: Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer, 114: 613-622, 2005.
23. Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, Slattery K, Qureshi M, Wei Y, Deng Y, Xiang J: Membrane-bound HSP70-engineeredmyeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumor immunity than exosomes released fromheat-shocked tumor cells expressing cytoplasmic HSP70. J Cell Mol Med, 2009; Jul 20 [Epub ahead of print].
24. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ: Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer, 85: 460-465, 2000.
25. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, François P, Abi-Aad A, Van Cangh P, Abbou CC, Chopin D: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer, 64: 60-64, 1995.
26. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M: Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res, 7: 23-31, 2001.
27. Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K: Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient. Anticancer Res, 29: 647-655, 2009.
28. André F,Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol, 172: 2126-2136, 2004.
29. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD, Zahorchak AF, Logar AJ, Wang Z, Watkins SC, Falo LD Jr, Thomson AW: Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood, 104: 3257-3266, 2004.
30. Théry C, Regnault A, Garin J,Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol, 147: 599-610, 1999.
31. Küng M, Stadelmann B, Brodbeck U, Bütikofer P: Addition of G418 and other aminoglycoside antibiotics to mammalian cells results in the release of GPI-anchored proteins. FEBS Lett, 409: 333-338, 1997.
32. Dai S, Zhou X, Wang B, Wang Q, Fu Y, Chen T, Wan T, Yu Y, Cao X: Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med, 84: 1067-1076, 2006.
33. Overwijk WW, Theoret MR, Restifo NP: The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am, 6: 76-80, 2000.
34. Fukao T, Koyasu S: Expression of functional IL-2 receptors onmature splenic dendritic cells. Eur J Immunol, 30: 1453-1457, 2000.
35. Granucci F, Andrews DM, Degli-Esposti MA, Ricciardi-Castagnoli P: IL-2 mediates adjuvant effect of dendritic cells. Trends Immunol, 23: 169-171. 2002.